Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pila Pharma AB's enterprise value is €5.12 Mil.
Pila Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.43 Mil. Therefore, Pila Pharma AB's EV-to-EBITDA for today is -3.59.
The historical rank and industry rank for Pila Pharma AB's EV-to-EBITDA or its related term are showing as below:
FRA:5KC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.05 Med: -2.9 Max: -0.45
Current: -3.61
During the past 8 years, the highest EV-to-EBITDA of Pila Pharma AB was -0.45. The lowest was -22.05. And the median was -2.90.
FRA:5KC's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 13.065
vs FRA:5KC: -3.61
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pila Pharma AB's PE Ratio (TTM) for today is calculated as:
Pila Pharma AB's share price for today is €0.112.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pila Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.057.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Pila Pharma AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5KC vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Pila Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pila Pharma AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pila Pharma AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pila Pharma AB's EV-to-EBITDA falls into.
Pila Pharma AB's current Enterprise Value is €5.12 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pila Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pila Pharma AB (FRA:5KC) has a EV-to-EBITDA of -3.59 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pila Pharma AB. According to the industry distribution chart, Pila Pharma AB ranks #999999 out of 400 companies in the Biotechnology industry.
Is Pila Pharma AB's EV-to-EBITDA too high?
Pila Pharma AB's current EV-to-EBITDA is -3.59. Based on the distribution chart, Pila Pharma AB ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pila Pharma AB has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Pila Pharma AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pila Pharma AB ranks #999999 out of 400 companies for EV-to-EBITDA. This places Pila Pharma AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.07, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pila Pharma AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pila Pharma AB's current EV-to-EBITDA is -3.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pila Pharma AB stock overvalued right now?
Pila Pharma AB (FRA:5KC) has a current EV-to-EBITDA of -3.59. The stock's GF Value™ is €0.16, compared to a current price of €0.11 — trading 30% below its estimated fair value. The current EV-to-EBITDA is -3.59. Pila Pharma AB's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Pila Pharma AB (FRA:5KC), the current EV-to-EBITDA is -3.59 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pila Pharma AB (FRA:5KC) Overvalued in 2026?
Based on GuruFocus' analysis, Pila Pharma AB stock appears to be undervalued.
The current stock price of €0.11 is trading 30% below its estimated GF Value™ of €0.16.
Key valuation signals for FRA:5KC:
EV-to-EBITDA: -3.59
GF Value™: €0.16 vs. price of €0.11 (30% below fair value)
No single metric tells the full story. See the FRA:5KC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
50GF Score
Get the complete analysis for FRA:5KC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5KC has been successfully added to your 
